Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2018-05-15 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1163 characters) and contains the header 'RNS Number : 1259O'. The content describes a 'Price Monitoring Extension' related to trading on the London Stock Exchange, which is a routine operational announcement concerning market mechanics rather than a core financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the specific financial or corporate action categories (like DIV, CAP, DIRS), the most appropriate fallback category is Regulatory Filings (RNS).
2018-05-15 English
Upcoming Investor Presentations
Regulatory Filings Classification · 1% confidence The document is a formal announcement disseminated via RNS (RNS Number : 8887N) on May 14, 2018. The content explicitly states that the CEO will be presenting at a series of 'upcoming investor evenings' and provides details and registration links for these events. Furthermore, it mentions that 'A copy of the latest investor presentation will be available from 12pm on 15 May 2018'. This structure—announcing future presentations and referencing an attached/forthcoming presentation—strongly indicates that the primary purpose of this filing is to inform the market about investor engagement activities, which aligns best with the Investor Presentation (IP) category, as it is directly promoting the content that will be shared in those presentations. Although it is an announcement, the subject matter is the presentation itself, making IP a better fit than the generic RPA or RNS, as the content is specifically about investor presentations.
2018-05-14 English
Verona Pharma plc : Miscellaneous
Investor Presentation Classification · 1% confidence The document is a press release issued by Verona Pharma plc announcing that it will present clinical trial data for its product candidate RPL554 at the American Thoracic Society International Conference (ATS). It details the poster presentation sessions, dates, and times. This type of announcement, which publicizes upcoming participation in a conference or presentation of preliminary/detailed data outside of a formal regulatory filing period (like 10-K or IR), is best classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it were summarizing financial results. Since this is an announcement about presenting scientific/clinical data at a conference, it functions as a specific type of investor communication. However, given the options, it is not a formal Earnings Release (ER) as it focuses on clinical data presentation, nor is it a formal Investor Presentation (IP) document itself, but rather an announcement *about* presentations. It is also not a short notice that requires the 'RPA' classification based on the 'MENU VS MEAL' rule, as the document is substantial (9877 chars) and contains detailed background information, forward-looking statements, and citation references, suggesting it is a substantive communication. In the context of financial filings, announcements detailing upcoming scientific presentations or data readouts are often grouped with Investor Presentations (IP) or sometimes treated as general Regulatory Filings (RNS) if no other category fits well. Since the content is highly specific to clinical trial data being presented to investors/the medical community, 'Investor Presentation (IP)' is the closest fit for the *subject matter* being communicated, even though this specific document is the *announcement* of the presentation. Given the available codes, and recognizing this is a proactive communication about company progress aimed at investors, IP is the most appropriate category for this type of scientific/clinical update announcement, as it precedes or accompanies the actual presentation materials. Revisiting the definitions: 'IP' is 'Investor Presentation'. This document announces participation in a conference where presentations will occur. If the document were the actual slides or a detailed report, IP would be certain. As an announcement of data presentation, it is a strong indicator of investor focus. If it were purely a regulatory update without scientific/financial focus, RNS would apply. Given the strong focus on clinical trial data and conference participation, IP is selected as the primary intent is investor/analyst communication regarding R&D progress.
2018-05-09 English
Filing of Patent
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated May 9, 2018. The content announces the 'Filing of Patent Cooperation Treaty ("PCT") patent application' for a drug reformulation. This is a specific corporate action announcement related to intellectual property and development, not a periodic financial report (like 10-K or IR), an earnings release (ER), or a general shareholder vote result (DVA). Since it is a specific, non-financial regulatory announcement distributed via the RNS system, and it doesn't fit the other specific categories (like DIRS, DIV, MANG, etc.), it falls best under the general regulatory announcement category, RNS, as it is explicitly marked as being provided by RNS and is a material, non-periodic update.
2018-05-09 English
Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
Earnings Release Classification · 1% confidence The document explicitly states it 'announces today an operational update and financial results for the three months ended March 31, 2018.' It provides key operational highlights (clinical trial data) and financial highlights (net cash, operating loss, loss per share) for a quarterly period. This structure is characteristic of an Earnings Release (ER), which provides initial announcements of periodical financial results, often accompanied by operational updates. While it contains financial data, it is presented as a press release announcing results, not the comprehensive report itself (which would be an IR or 10-K). The inclusion of conference call details further supports this being an earnings announcement. Q1 2018
2018-05-08 English
Verona Pharma to Present at Bio€quity Europe 2018
Regulatory Filings Classification · 1% confidence The document is a short press release from Verona Pharma plc announcing that its Chief Financial Officer, Piers Morgan, will present at the Bio€quity Europe 2018 conference on May 15th, 2018. It provides details about the presentation time and location, along with boilerplate information about the company and contact details. This type of announcement, which informs the public about an upcoming investor event (a presentation at a conference), is typically classified as an Investor Presentation (IP) announcement or, more broadly, a general regulatory filing. Since the document itself is not the presentation slides but an announcement *about* the presentation, and it doesn't fit neatly into specific financial reporting categories (like 10-K, ER, or DIV), it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if the focus is on the event itself. Given the context of providing information to investors about an upcoming presentation, IP is a strong candidate, but RNS serves as the general regulatory announcement fallback. However, since the content is purely about an upcoming investor event/presentation, IP (Investor Presentation) is the most specific fit for the *subject matter*, even if it's just the announcement of it. Given the short length and the nature of announcing participation in an investor event, RNS (Regulatory Filings) is often used for such non-standard announcements, but IP covers the substance better. I will lean towards RNS as it is a general announcement distributed via GlobeNewswire that doesn't contain the actual presentation material, fitting the 'miscellaneous filing' criteria better than the 'IP' code which usually implies the presentation document itself. However, upon re-reviewing the definitions, IP is for the 'Detailed presentation for investors focusing on financials, strategy, and market position.' This document is an announcement *about* a presentation. Since it is a short announcement about an investor event, RNS is the safest general regulatory classification, but if we consider the intent, it relates directly to investor relations activities. Given the options, and the fact that it's a brief announcement about an executive speaking at an investor conference, RNS (Regulatory Filings) is the most appropriate general classification for this type of market communication that isn't a core financial report or a specific insider trade/dividend notice.
2018-05-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.